{
    "root": "7fb8acac-13ca-47ca-8b06-d12900d4943b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Darunavir",
    "value": "20231121",
    "ingredients": [
        {
            "name": "DARUNAVIR",
            "code": "YO603Y8113",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_367163"
        },
        {
            "name": "CROSPOVIDONE (12 MPA.S AT 5%)",
            "code": "40UAA97IT9"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "darunavir , co-administered ritonavir ( darunavir/ritonavir ) , combination antiretroviral agents , indicated treatment human immunodeficiency virus ( hiv-1 ) infection adult pediatric patients 3 years age older [ ( 8.4 ) ( 14 ) ] .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "immunodeficiency",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_101997"
            }
        ]
    },
    "contraindications": {
        "text": "testing : treatment-experienced patients , treatment history genotypic and/or phenotypic testing recommended prior initiation therapy darunavir/ritonavir assess susceptibility hiv-1 virus . ( 2.1 , 12.4 ) monitor serum liver chemistry tests therapy darunavir/ritonavir . ( 2.1 , 2.2 , 5.2 ) treatment-na\u00efve adult patients treatment-experienced adult patients darunavir resistance associated substitutions : 800 mg ( one 800 mg tablet ) taken ritonavir 100 mg daily food . ( 2.3 ) treatment-experienced adult patients least one darunavir resistance associated substitution : 600 mg ( one 600 mg tablet ) taken ritonavir 100 mg twice daily food . ( 2.3 ) pregnant patients : 600 mg ( one 600 mg tablet ) taken ritonavir 100 mg twice daily food . ( 2.4 ) pediatric patients ( 3 years less 18 years age weighing least 10 kg ) : darunavir ritonavir based body weight exceed adult dose . darunavir tablets taken ritonavir food . ( 2.5 ) darunavir/ritonavir recommended patients severe hepatic impairment . ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "darunavir tablets , 600 mg supplied orange colored , oval shaped , film-coated tablets , debossed \u201c ac13 \u201d one side plain side . available follows : bottles 60 : ndc 60219-1144-6 darunavir tablets , 800 mg supplied dark red colored , oval shaped , film-coated tablets , debossed \u201c ac14 \u201d one side plain side . available follows : bottles 30 : ndc 60219-1145-3 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . keep medications reach children .",
    "adverseReactions": "co-administration darunavir/ritonavir contraindicated drugs highly dependent cyp3a clearance elevated plasma concentrations associated serious and/or life-threatening events ( narrow therapeutic index ) . examples drugs contraindicated drugs ( may lead reduced efficacy darunavir ) listed [ ( 7.3 ) ] . due need co-administration darunavir ritonavir , please refer ritonavir prescribing information description ritonavir . alpha 1-adrenoreceptor antagonist : alfuzosin anti-gout : colchicine , patients renal and/or hepatic impairment antimycobacterial : rifampin antipsychotics : lurasidone , pimozide cardiac disorders : dronedarone , ivabradine , ranolazine ergot derivatives , e.g . , dihydroergotamine , ergotamine , methylergonovine herbal product : st. john \u2019 wort ( hypericum perforatum ) hepatitis c direct acting antiviral : elbasvir/grazoprevir lipid modifying agents : lomitapide , lovastatin , simvastatin opioid antagonist : naloxegol pde-5 inhibitor : sildenafil used treatment pulmonary arterial hypertension sedatives/hypnotics : orally administered midazolam , triazolam",
    "indications_original": "Darunavir, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations (8.4)\u00a0and \n                        Clinical Studies (14)].",
    "contraindications_original": "Testing: In treatment-experienced patients, treatment history genotypic and/or phenotypic testing is recommended prior to initiation of therapy with darunavir/ritonavir to assess drug susceptibility of the HIV-1 virus. ( 2.1 , 12.4 ) Monitor serum liver chemistry tests before and during therapy with darunavir/ritonavir. ( 2.1 , 2.2 , 5.2 ) Treatment-na\u00efve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet) taken with ritonavir 100 mg once daily and with food. ( 2.3 ) Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. ( 2.3 ) Pregnant patients: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. ( 2.4 ) Pediatric patients (3 years to less than 18 years of age and weighing at least 10 kg): dosage of darunavir and ritonavir is based on body weight and should not exceed the adult dose. Darunavir tablets should be taken with ritonavir and with food. ( 2.5 ) Darunavir/ritonavir is not recommended for use in patients with severe hepatic impairment. ( 2.6 )",
    "warningsAndPrecautions_original": "Darunavir Tablets, 600 mg are supplied as orange colored, oval shaped, film-coated tablets, debossed with \u201cAC13\u201d on one side and plain on the other side.\n                  They are available as follows:\n                  Bottles of 60:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 60219-1144-6\n                  Darunavir Tablets, 800 mg are supplied as dark red colored, oval shaped, film-coated tablets, debossed with \u201cAC14\u201d on one side and plain on the other side. \n                  They are available as follows:\n                  Bottles of 30:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 60219-1145-3\n                  \n                     Storage \n                  \n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                     Keep this and all medications out of the reach of children.",
    "adverseReactions_original": "Co-administration of darunavir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). Examples of these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below [see Drug Interactions (7.3)]. Due to the need for co-administration of darunavir with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications.\n                  \n                     Alpha 1-adrenoreceptor antagonist: alfuzosin \n                     Anti-gout: colchicine, in patients with renal and/or hepatic impairment \n                     Antimycobacterial: rifampin \n                     Antipsychotics: lurasidone, pimozide \n                     Cardiac Disorders: dronedarone, ivabradine, ranolazine\n                     Ergot derivatives, e.g., dihydroergotamine, ergotamine, methylergonovine \n                     \u00a0Herbal product: St. John\u2019s wort (Hypericum perforatum)\n                     Hepatitis C direct acting antiviral: elbasvir/grazoprevir \n                     Lipid modifying agents: lomitapide, lovastatin, simvastatin\n                     Opioid Antagonist: naloxegol\n                     PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension \n                     Sedatives/hypnotics: orally administered midazolam, triazolam",
    "drug": [
        {
            "name": "Darunavir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_367163"
        }
    ]
}